Sort
15,273 grants matching “antimicrobial resistance”
Designing new aminoglycosides to alleviate inner ear toxicity
$592,955Anthony J Ricci · Stanford University · R01 · FY2018 · DC
Development of an antimicrobial peptide therapeutic for Pseudomonas infections
$592,713H. Anne Pereira · University Of Oklahoma Hlth Sciences Ctr · U01 · FY2008 · AI
Antibiotic Discovery
$592,607Samuel I. Miller · University Of Washington · U54 · FY2008 · AI
Evolution and acquistion of drug resistance in MRSA
$592,338Rockefeller University · R01 · FY2005 · AI
Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children
$592,245Judd L. Walson · University Of Washington · R01 · FY2019 · HD
Regulatory Role of Tandem Tryptophan Codons in Chlamydial Persistence
$592,167Reynaldo A Carabeo · University Of Nebraska Medical Center · R01 · FY2022 · AI
Designing new aminoglycosides to alleviate inner ear toxicity
$592,155Anthony J Ricci · Stanford University · R01 · FY2020 · DC
Excellence in Research for Emerging and Reemerging Diseases of Public Health Interest in Colombia at the National Institute of Health
$592,000Martha Ospina · Colombian National Institute Of Health · U01 · FY2020 · GH
Control of Endoplasmic Reticulum Tubule Formation by Legionella pneumophila
$591,891Ralph R Isberg · Tufts University Boston · R01 · FY2017 · AI
Control of Endoplasmic Reticulum Tubule Formation by Legionella pneumophila
$591,891Ralph R Isberg · Tufts University Boston · R01 · FY2018 · AI
Mode of Action Core
$591,851Bruce Steven Klein · University Of Wisconsin-Madison · U19 · FY2021 · AI
Fecal microbiota transplant for Alcohol-Associated Cirrhosis
$591,596Jasmohan S Bajaj · Virginia Commonwealth University · R01 · FY2024 · AA
Oxidative Stress Responses in Oral Streptococci
$591,406Robert G Quivey · University Of Rochester · R01 · FY2015 · DE
A Novel Remedy for Periodontal Bone Loss
$591,125Deepak Saxena · Periomics Care, Llc · R42 · FY2022 · DE
Identification and Characterization of Genes Required for Listeria monocytogenes Cytosolic Survival
$591,036John-Demian Sauer · University Of Wisconsin-Madison · R01 · FY2018 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$590,928Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2012 · AI
Metabolic Assessment of Anti-Microbial Susceptibility within One Cell Cycle
$590,895Ji-Xin Cheng · Boston University (Charles River Campus) · R01 · FY2020 · AI
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
$590,745Michael Karin · University Of California, San Diego · R37 · FY2018 · AI
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
$590,745Michael Karin · University Of California, San Diego · R37 · FY2022 · AI
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
$590,745Michael Karin · University Of California, San Diego · R37 · FY2020 · AI
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
$590,745Michael Karin · University Of California, San Diego · R37 · FY2019 · AI
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
$590,745Michael Karin · University Of California, San Diego · R37 · FY2021 · AI
Overcoming Resistance to Novel Bacterial Topoisomerase Inhibitors
$590,675Mark J. Mitton-Fry · Ohio State University · R01 · FY2025 · AI
Overcoming Resistance to Novel Bacterial Topoisomerase Inhibitors
$590,675Mark J. Mitton-Fry · Ohio State University · R01 · FY2024 · AI
Identifying the pathways associated with bacterial antibiotic persistence within host tissues
$590,636Kim Davis · Johns Hopkins University · R01 · FY2023 · AI